卢比内克丁的营销后安全性评估:基于FAERS数据库的药监测分析
Zhao Li1, Changying Guo1, Xingfei Liu1,2
1Department of Thoracic Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, China.
Frontiers in pharmacology
|March 29, 2024
概括
这项研究分析了FDA对lurbinectedin的不良事件报告,揭示了已知的副作用以及肺癌患者瘤溶解综合征的新安全信号. 这些发现有助于临床实践和未来的研究.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 临床安全 临床安全
背景情况:
- 2020年6月15日,Lurbinectedin获得了FDA的批准,用于转移性小细胞肺癌的白金化疗后化疗.
- 在广泛的患者群体中对卢宾克丁的营销后安全性数据仍然有限.
- 这项研究使用FDA不良事件报告系统 (FAERS) 数据库调查了lurbinectedin的不良事件 (AE).
研究的目的:
- 在现实世界,市场营销后环境中全面评估卢比内克丁的安全性.
- 为了识别和量化与lurbinectedin治疗相关的潜在不良事件.
- 检测以前在临床试验或标签上没有报告的新安全信号.
主要方法:
- 从FAERS数据库 (2020年6月至2023年9月) 的数据中提取了lurbinectedin.
- 采用了四种不成比例分析算法:ROR,PRR,多项性马鱼缩小器和贝叶斯信任传播神经网络.
- 在23个系统器官类 (SOCs) 中,对lurbinectedin的量化AE信号.
主要成果:
- 从5,801,535个AE报告中分析了511个与氨酸相关的AE.
- 在23个SOC中检测到47个lurbinectedin诱导的AE信号;血液和淋巴系统障碍符合所有算法.
- 确定死亡是最常见的AE;扩散显示出最强的ROR信号. 还检测到了瘤溶解综合征的一种新信号.
结论:
- 该研究提供了对lurbinectedin营销后安全性的强有力的评估.
- 确定已知的副作用和瘤溶解综合征的新型未报告的安全信号.
- 这些发现增强了对Lurbinectedin使用的临床指导,并为未来的研究方向提供了信息.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.3K
08:11Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay
Published on: September 6, 2016
18.7K
相关概念视频
01:19Pharmacovigilance
830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830
01:25Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K